Fusion Pharmaceuticals has appointed James O’Leary as its chief medical officer. O’Leary’s experience includes roles at ImmunoGen (NASDAQ: IMGN), Idera Pharmaceuticals (NASDAQ: IDRA), Array Biopharma, and Deciphera (NASDAQ: DCPH), Takeda (NYSE: TAK), Bayer, and Pfizer (NYSE: PFE). Most recently O’Leary was a global project team leader for a late-stage asset directing global strategy and regulatory approvals at Takeda Pharmaceutical (NYSE: TAK).
Fusion, which has sites in Boston and Hamilton, Ontario, is developing new radiopharmaceuticals—drugs containing radioactive isotopes—to treat a range of cancer types. Lead program FPI-1434 is in Phase 1 testing, a study financed by a more than $100 million Series B financing Fusion completed in 2019.